Therapeutic Solutions International (TSOI) S-1/A 6 Feb 24 IPO registration (amended) Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2023
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	We initially registered on Form S-1 (File No. 333-268070) (i) the issuance and sale of up to 555,000,000 shares of our Common Stock, par value $0.0001 per share (“Common Stock) offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 and pursuant to a securities purchase agreement which provides the right to an aggregate gross proceeds of up to $10.0 million from the sale of our Common Stock to the selling shareholder, GHS Investments, LLC (“GHS”) (the “GHS Purchase Agreement”) entered into on September 19, 2022. The S-1, as amended, became effective February 15, 2023.
Entity Registrant Name	Therapeutic Solutions International, Inc.
Entity Central Index Key	0001419051
Entity Tax Identification Number	45-1226465
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	701 Wild Rose Lane
Entity Address, City or Town	Elk City
Entity Address, State or Province	ID
Entity Address, Postal Zip Code	83525
City Area Code	760
Local Phone Number	295-7208
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	5348 Vegas Dr.
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89108
City Area Code	702)
Local Phone Number	871-8678
Contact Personnel Name	EastBiz.com, Inc.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 90,138	$ 18,040	$ 94,036
Restricted cash		11,003	10,223
Accounts receivable	21,764	25,398	16,613
Inventory	26,418	42,428	39,817
Prepaid expenses and other current assets	42,661	212,352	959,307
Total current assets	180,981	309,221	1,119,996
Property and equipment, net	377,076	273,078	284,024
Right-of-use asset	131,818	8,612	34,184
Other assets	2,784,502	3,014,620	277,571
Total assets	3,474,377	3,605,531	1,715,775
Current liabilities:
Accrued expenses and other current liabilities	601,446	531,783	487,208
Lease liability	26,786	8,612	25,374
Convertible notes payable, net of discount of $175,063 and $225,800, at December 31, 2022 and 2021, respectively	46,139	65,187	79,200
Derivative liabilities	292,699	202,144	531,525
Total current liabilities	2,053,239	2,210,237	2,496,415
LONG TERM LIABILITIES
Notes payable, net of current portion	6,810	10,507	15,532
Lease liability, net of current portion	105,032		8,810
TOTAL LIABILITIES	2,165,081	2,220,744	2,520,757
Commitments and contingencies
Shareholders’ Equity (Deficit):
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively
Common stock, $0.001 par value; 3,500,000,000 shares authorized; 2,617,390,830 and 2,311,123,860 shares issued and outstanding at December 31, 2022 and 2021, respectively.	3,450,666	2,617,392	2,311,125
Additional paid-in capital	17,282,608	16,334,129	10,899,139
Shares to be issued	13,074	126,324
Subscription receivable	(21,000)	(21,000)	(21,000)
Accumulated deficit	(19,414,380)	(17,672,058)	(13,994,246)
Total shareholders’ equity (deficit)	1,310,968	1,384,787	(804,982)
Non-controlling interest	(1,672)
Total shareholders’ equity - Therapeutic Solutions International, Inc.	1,309,296	1,384,787	(804,982)
Total liabilities and shareholders’ equity (deficit)	3,474,377	3,605,531	1,715,775
Nonrelated Party [Member]
Current liabilities:
Accounts payable-related parties	374,459	401,992	394,035
Notes payable-related parties, net	4,638	4,638	4,071
Related Party [Member]
Current liabilities:
Accounts payable-related parties	7,206	7,209	9,791
Notes payable-related parties, net	$ 699,866	$ 988,672	$ 965,211

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount, current	$ 157,861	$ 175,063	$ 225,800
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued	2	2	0
Preferred stock, shares outstanding	2	2	0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	5,500,000,000	3,500,000,000	3,500,000,000
Common stock, shares, issued	3,450,665,355	2,617,390,830	2,311,123,860
Common stock, shares, outstanding	3,450,665,355	2,617,390,830	2,311,123,860

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 25,730	$ 74,541	$ 75,161	$ 198,188	$ 206,767	$ 145,956
Cost of goods sold	7,052	8,790	26,217	33,437	79,440	42,544
Gross profit	18,678	65,751	48,944	164,751	127,327	103,412
Operating expenses:
General and administrative	127,204	204,838	359,948	388,561	491,928	138,710
Salaries, wages, and related costs	111,220	110,108	335,699	336,926	444,865	436,555
Consulting fees	20,150	88,158	142,907	317,284	432,033	264,540
Legal and professional fees	68,560	106,795	229,952	266,158	397,302	773,203
Research and development	148,879	275,071	410,146	1,177,123	1,441,128	794,750
Total operating expenses	476,013	784,970	1,478,652	2,486,052	3,207,256	2,407,758
Loss from operations	(457,335)	(719,219)	(1,429,708)	(2,321,301)	(3,079,929)	(2,304,346)
Other income (expense):
Loss on derivative liabilities	(2,336)	(26,867)	21,939	(136,583)	(131,475)	(539,006)
Change in fair value of derivative liabilities	(60,124)	(32,205)	(93,836)	233,303	291,123	494,501
Interest expense	(83,062)	(167,371)	(327,135)	(512,761)	(646,089)	(611,794)
Other expense					(110,642)
Gain on extinguishment of debt			85,546
Total other income (expense)	(145,522)	(226,443)	(313,486)	(416,041)	(597,083)	(656,299)
LOSS BEFORE PROVISION FOR INCOME TAXES	(602,857)	(945,662)	(1,743,194)	(2,737,342)	(3,677,012)	(2,960,645)
Provision for income taxes		800	800	800	800	800
Net loss	(602,857)	(946,462)	(1,743,994)	(2,738,142)	$ (3,677,812)	$ (2,961,445)
Loss attributable to non-controlling interest	(816)		(1,672)
Net loss attributable to Therapeutic Solutions International, Inc.	$ (602,041)	$ (946,462)	$ (1,742,322)	$ (2,738,142)
Net loss per share - basic and diluted	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Net loss per share - diluted	$ 0	$ 0	$ 0	$ 0
Weighted average shares outstanding - basic and diluted	3,286,909,395	2,565,663,048	2,987,459,958	2,501,116,667	2,528,062,958	2,263,126,970
Weighted average shares outstanding - diluted	3,286,909,395	2,565,663,048	2,987,459,958	2,501,116,667

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Shares to be Issued [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance, shares at Dec. 31, 2020		2,233,741,391
Balance at Dec. 31, 2020		$ 2,233,742	$ 7,041,960		$ (21,000)	$ (11,032,801)		$ (1,778,099)
Common stock issued for services		$ 21,000	837,900					858,900
Common stock issued for services, shares		21,000,000
Common stock issued for prepaid fees		$ 20,000	1,452,450					1,472,450
Common stock issued for prepaid fees, shares		20,000,000
Common stock issued for salaries		$ 8,342	231,457					239,799
Common stock issued for salaries, shares		8,341,723
Common stock issued for cash		$ 4,850	280,649					285,499
Common stock issued for cash, shares		4,850,075
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 21,691	508,044					529,735
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		21,690,671
Net loss						(2,961,445)		(2,961,445)
Common stock issued for land development		$ 1,500	57,400					58,900
Common stock issued for land development, shares		1,500,000
Relief of derivative liabilities			489,279					489,279
Ending balance, value at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)		(804,982)
Balance, shares at Dec. 31, 2021		2,311,123,860
Balance at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)		(804,982)
Common stock issued for services		$ 25,303	482,775					508,078
Common stock issued for services, shares		25,302,577
Common stock issued for prepaid fees		$ 11,000	231,320					242,320
Common stock issued for prepaid fees, shares		11,000,000
Common stock issued for salaries		$ 1,034	28,965					29,999
Common stock issued for salaries, shares		1,034,482
Common stock issued for cash		$ 44,500	400,500					445,000
Common stock issued for cash, shares		44,500,000
Common stock issued for license		$ 149,402	2,958,168					3,107,570
Common stock issued for license, shares		149,402,390
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 41,700	901,732					943,432
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		41,700,228
Common stock issued for land development		$ 4,000	46,400					50,400
Common stock issued for land development, shares		4,000,000
Net loss						(2,738,142)		(2,738,142)
Ending balance, value at Sep. 30, 2022		$ 2,588,064	15,948,999		(21,000)	(16,732,388)		1,783,675
Balance, shares at Sep. 30, 2022		2,588,063,537
Beginning balance, value at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)		(804,982)
Balance, shares at Dec. 31, 2021		2,311,123,860
Balance at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)		(804,982)
Common stock issued for services		$ 32,413	557,107	102,000				691,520
Common stock issued for services, shares		32,412,577
Common stock issued for prepaid fees		$ 11,000	231,320					242,320
Common stock issued for prepaid fees, shares		11,000,000
Common stock issued for salaries		$ 4,812	62,587					67,399
Common stock issued for salaries, shares		4,812,259
Common stock issued for cash		$ 44,500	400,500					445,000
Common stock issued for cash, shares		44,500,000
Common stock issued for license		$ 149,402	2,958,168					3,107,570
Common stock issued for license, shares		149,402,390
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 64,140	1,225,308	24,324				1,313,772
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		64,139,744
Net loss						(3,677,812)		(3,677,812)
Issuance of preferred stock
Issuance of preferred stock, shares	2
Ending balance, value at Dec. 31, 2022		$ 2,617,392	16,334,129	126,324	(21,000)	(17,672,058)		1,384,787
Balance, shares at Dec. 31, 2022	2	2,617,390,830
Balance at Dec. 31, 2022		$ 2,617,392	16,334,129	126,324	(21,000)	(17,672,058)		1,384,787
Beginning balance, value at Jun. 30, 2022		$ 2,552,228	15,467,138		(21,000)	(15,785,926)		2,212,440
Balance, shares at Jun. 30, 2022		2,552,228,460
Common stock issued for services		$ 9,303	91,575					100,878
Common stock issued for services, shares		9,302,577
Common stock issued for prepaid fees		$ 5,000	88,500					93,500
Common stock issued for prepaid fees, shares		5,000,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 17,533	255,386					272,919
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		17,532,500
Common stock issued for land development		$ 4,000	46,400					50,400
Common stock issued for land development, shares		4,000,000
Net loss						(946,462)		(946,462)
Ending balance, value at Sep. 30, 2022		$ 2,588,064	15,948,999		(21,000)	(16,732,388)		1,783,675
Balance, shares at Sep. 30, 2022		2,588,063,537
Beginning balance, value at Dec. 31, 2022		$ 2,617,392	16,334,129	126,324	(21,000)	(17,672,058)		1,384,787
Balance, shares at Dec. 31, 2022	2	2,617,390,830
Common stock issued for services		$ 47,757	136,654	(98,250)				86,161
Common stock issued for services, shares		47,757,394
Common stock issued for salaries		$ 4,082	15,918					20,000
Common stock issued for salaries, shares		4,081,632
Common stock issued for cash		$ 445,180	232,198					677,378
Common stock issued for cash, shares		445,180,614
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 276,255	525,878	(15,000)				787,133
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		276,254,885
Common stock issued for land development		$ 60,000	36,000					96,000
Common stock issued for land development, shares		60,000,000
Net loss						(1,742,322)	(1,672)	(1,743,994)
Common stock issued by subsidiary for services			1,831					1,831
Ending balance, value at Sep. 30, 2023		$ 3,450,666	17,282,608	13,074	(21,000)	(19,414,380)	(1,672)	1,309,296
Balance, shares at Sep. 30, 2023	2	3,450,665,355
Balance at Sep. 30, 2023								1,310,968
Beginning balance, value at Jun. 30, 2023		$ 3,134,045	17,181,978	9,324	(21,000)	(18,812,339)	(856)	1,491,152
Balance, shares at Jun. 30, 2023	2	3,134,044,074
Common stock issued for services		$ 1,757	1,054	3,750				6,561
Common stock issued for services, shares		1,757,394
Common stock issued for prepaid fees
Common stock issued for salaries
Common stock issued for cash		$ 175,089	13,937					189,026
Common stock issued for cash, shares		175,089,179
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 79,775	49,639					129,414
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		79,774,708
Common stock issued for land development		$ 60,000	36,000					96,000
Common stock issued for land development, shares		60,000,000
Net loss						(602,041)	(816)	(602,857)
Common stock issued by subsidiary for services
Ending balance, value at Sep. 30, 2023		$ 3,450,666	$ 17,282,608	$ 13,074	$ (21,000)	$ (19,414,380)	$ (1,672)	1,309,296
Balance, shares at Sep. 30, 2023	2	3,450,665,355
Balance at Sep. 30, 2023								$ 1,310,968

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (1,743,994)	$ (2,738,142)	$ (3,677,812)	$ (2,961,445)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation to consultants		311,078	380,820	397,750
Stock-based compensation to related parties	86,161	197,000	310,700	461,150
Loss on derivative liabilities	(21,939)	136,583	131,475	539,006
Change in fair value of derivative liabilities	93,836	(233,303)	(291,123)	(494,501)
Gain on extinguishment of debt	(85,546)
Amortization of prepaid stock-based compensation	112,971	868,089	951,748	480,135
Amortization of debt discount	299,267	461,058	593,463	541,612
Patent amortization	222,581	191,192	233,685	11,295
Depreciation	8,161	3,489	10,946	6,772
Changes in operating assets and liabilities:
Accounts receivable	3,634	(25,769)	(8,785)	(14,172)
Inventory	16,010	(5,126)	(2,611)	(34,418)
Prepaid expenses and other current assets	69,595	73,807	174,364	64,777
Right-of-use asset	23,038	19,113	25,572	24,792
Accounts payable	(27,535)	(30,051)	15,166	91,557
Accounts payable - related parties	(3)	(2,552)	(9,791)	2,581
Accrued expenses and other current liabilities	117,538	139,405	169,451	188,979
Lease liability	(23,038)	(19,113)	(25,572)	(24,792)
Net cash used in operating activities	(849,263)	(653,242)	(1,018,304)	(718,922)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(16,158)			(260,565)
Deposits				4,015
Purchase of license		(200,000)
Issuance of note receivable	(3,507)
Net cash used in investing activities	(19,665)	(200,000)		(256,550)
Cash flows from financing activities
Payments on notes payable to related party	(17)	(2,444)	(2,453)	(4,799)
Proceeds from notes payable to related party	5,609
Proceeds from convertible notes payable	250,750	415,000	505,000	538,750
Payments on notes payable	(3,697)	(3,324)	(4,459)	(2,068)
Proceeds from sale of common stock	677,378	445,000	445,000	285,499
Net cash provided by financing activities	930,023	854,232	943,088	817,382
Net increase (decrease) in cash, cash equivalents and restricted cash	61,095	990	(75,216)	(158,090)
Cash, cash equivalents and restricted cash at beginning of period	29,043	104,259	104,259	262,349
Cash, cash equivalents and restricted cash at end of period	90,138	105,249	29,043	104,259
Supplemental cash flow information:
Cash paid for interest	2,475	2,357	3,173	3,312
Cash paid for income taxes		800	800	800
Non-cash investing and financing transactions:
Original issuance discount on convertible notes payable	32,500	30,500	39,000	33,500
Debt discount recorded in connection with derivative liability	249,565	415,000	503,726	538,750
Common stock issued in conversion of convertible notes payable and interest	787,133	943,431	1,313,772	1,019,014
Property and equipment purchased with note payable				21,671
Common stock issued for prepaid fees	1,831	242,320	242,320	1,472,450
Common stock issued for accrued salaries	20,000	29,999	67,399	239,799
Accrued interest added to principal	11,148	19,436	25,914	25,912
Common stock issued for license		3,107,570	3,107,570
Common stock issued for land development	96,000	50,400		58,900
Right of use asset and lease liability	146,244
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	90,138	94,246	18,040	94,036
Restricted cash		11,003	11,003	10,223
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows:	$ 90,138	$ 105,249	$ 29,043	$ 104,259

Organization and Business Descr

Organization and Business Description	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Description	Note 1 – Organization and Business Description Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 Business Description Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health. Nutraceutical Division Regenerative Medicine The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Subsequent to this acquisition the Company has filed an additional 22 patents on this population of unique mesenchymal like stromal cells. Immunotherapies TSOI has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to parkinson’s disease developed on our StemVacs platform. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 Management does not expect existing cash as of September 30, 2023, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of September 30, 2023, the Company has incurred losses totaling $ 19.4	Note 1 – Organization and Business Description Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 Business Description Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health. Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE. On Augus t the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%. In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.” The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells. Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production. On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Management does not expect existing cash as of December 31, 2022 or as of March 31, 2023 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2022, the Company has incurred losses totaling $ 17.3

Basis of presentation and signi

Basis of presentation and significant accounting policies	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of presentation and significant accounting policies	Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc., its wholly owned subsidiaries, and its 68% owned subsidiary Res Nova Bio, Inc. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Our estimate of the provision for returns is based upon our most recent historical experience of actual customer returns. Additionally, we consider other factors when estimating our current period return provision, including levels of inventory in our distribution channel as well as significant market changes which may impact future expected returns, and make adjustments to our current period provision for returns when it appears product returns may differ from our original estimates. These returns have not been significant to the Company’s revenues in the accompanying financial statements. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2023 and 2022, as disclosed in Note 7 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 292,699 202,144 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, 2023 and December 31, 2022, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the three months ended September 30, 2023 Schedule of Change in Derivative Liability Balance, December 31, 2022 $ 202,144 Issuance of new derivative liabilities 328,433 Conversions (331,714 ) Change in fair market value of derivative liabilities 93,836 Balance, September 30, 2023 $ 292,699 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Non-Controlling Interests Non-controlling interests disclosed within the consolidated statement of operations represent the minority ownership’s 32 Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of September 30, 2023, and 2022, a total of 1,259,591,300 211,919,728 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 Depreciation and Amortization Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Amortization is computed using the straight-line method over the term of the agreement. Depreciation expense for the nine months ended September 30, 2023, and 2022 was $ 8,161 3,489 Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the nine months ended September 30, 2023, and 2022 was $ 222,581 191,192 Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 410,146 1,177,123 Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 131,818 Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt —Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This update simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature and for convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this update amends the diluted earnings per share calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt the requirements of ASU 2020-06 using either a full or modified retrospective approach, and it is effective for public businesses, excluding entities eligible to be smaller reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The accounting guidance has been adopted with no significant financial statement impact. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023	Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries. Accounts Receivable Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. The Company recorded an allowance for doubtful accounts of $ 6,807 Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail. Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Returns. Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 202,144 531,525 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2022 and 2021, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2022 and 2021: Schedule of Change in Derivative Liability Balance, December 31, 2020 $ 437,549 Issuance of new derivative liabilities 1,077,756 Conversions (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 531,525 Issuance of new derivative liabilities 674,971 Conversions (713,229 ) Change in fair market value of derivative liabilities (291,123 ) Balance, December 31, 2022 $ 202,144 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2022 and 2021, a total of 267,136,056 95,273,690 Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $ 10,946 6,772 Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $ 233,685 11,295 Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Shipping and Handling The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within general administrative expenses. Advertising Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $ 4,132 0 Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 1,441,128 794,750 Income Taxes The Company accounts for income taxes under ASC 70 “Income Taxes” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 8,612

Prepaid expense and other curre

Prepaid expense and other current assets	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expense And Other Current Assets
Prepaid expense and other current assets	Note 3 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets September 30, 2023 December 31, 2022 Prepaid consulting $ 16,939 $ 148,550 Insurance 1,601 1,141 Prepaid costs and other 24,121 62,661 Total $ 42,661 $ 212,352 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023	Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets December 31, 2022 December 31, 2021 Prepaid consulting $ 148,550 $ 930,893 Insurance 1,141 987 Prepaid costs 62,661 27,427 Total $ 212,352 $ 959,307

Fixed assets

Fixed assets	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Fixed assets	Note 4 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets September 30, 2023 December 31, 2022 Land $ 347,381 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 6,135 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 413,517 301,359 Accumulated depreciation (36,441 ) (28,281 ) Property and equipment, net $ 377,076 $ 273,078 Depreciation expense was $ 8,161 3,489	Note 5 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets December 31, 2022 December 31, 2021 Land $ 235,223 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 301,359 301,159 Accumulated depreciation (28,281 ) (17,135 ) Property and equipment, net $ 273,078 $ 284,024 Depreciation expense was $ 10,946 6,772

Other assets

Other assets	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other assets	Note 5 – Other assets Other assets consist of the following: Schedule of Other Assets September 30, 2023 December 31, 2022 Prepaid consulting $ - $ 7,537 Deposit 4,123 4,123 Licenses, net 2,780,379 3,002,960 Total $ 2,784,502 $ 3,014,620 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses September 30, 2023 December 31, 2022 License $ 3,261,122 $ 3,261,122 Accumulated amortization (480,743 ) (258,162 ) Licenses, net $ 2,780,379 $ 3,002,960 Amortization expense for the nine months ended September 30, 2023, and 2022 was $ 222,581 191,192	Note 6 – Other assets Other assets consist of the following: Schedule of Other Assets December 31, 2022 December 31, 2021 Prepaid consulting $ 7,537 $ 108,673 Deposit 4,123 39,823 Licenses, net 3,002,960 129,075 Total $ 3,014,620 $ 277,571 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses December 31, 2022 December 31, 2021 Licenses $ 3,261,122 $ 153,552 Accumulated amortization (258,162 ) (24,477 ) Licenses, net $ 3,002,960 $ 129,075 Amortization expense for the years ended December 31, 2022 and 2021 was $ 233,685 24,477 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI. On February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on September 15, 2021. Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued 149,402,390 shares of common stock, valued at $ 0.0208 per share, for the EPLA, with a final value of the license being recorded at $ 3,107,570 . The Patent expires December 31, 2032 . The Exclusive Patent License to the Jadi Cell is for use under the designated areas of all applicable Lung Pathology. The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2 and will be amortized over the 10 year life of the Patent. As of March 25, 2022, we entered into a asset transfer and license agreement, which will be amortized over the life of the agreement. The agreement is until March 24, 2027 . The Company has made an initial payment of $ 200,000 . Within six months, the Company will make a second payment of $ 1.8 million. The agreement is in default and the initial payment of $200,000 was expensed to research & development.

Notes Payable-Related Party

Notes Payable-Related Party	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Notes Payable-Related Party	Note 6 - Notes Payable-Related Party At September 30, 2023 and December 31, 2022, the Company has unsecured interest-bearing demand notes outstanding to certain officers and directors amounting to $ 694,257 988,672 3,956 12,956	Note 8 – Notes payable-related parties Notes Payable-Related Party Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2022 December 31, 2021 $ - $ 2,356 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ - $ 2,356 One notes payable – Chief Executive Officer, unsecured, including interest at 8 10 December 31, 2019 29,090 27,577 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,448 534,544 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 124,800 118,400 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 30,334 282,334 988,672 965,211 $ 988,672 $ 965,211 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 7 – Convertible Notes Payable At various times during the nine months ended September 30, 2023, the Company entered into convertible promissory notes with principal amounts totaling $ 283,250 250,750 32,500 10 mature on dates ranging from April 11, 2024, to September 29, 2024 The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. 1,259,591,300 Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the notes issued during the nine months ended September 30, 2023, the Company valued the conversion feature on the date of issuance resulting in an initial liability of $ 628,437 78,868 0.0008 0.0034 0.0011 0.006 0 124 160 4.67 5.46 one year THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 During the nine months ended September 30, 2023, convertible notes with principal and accrued interest balances totaling $ 338,577 were converted into 218,504,885 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the fair value of the shares of common stock issued in excess or deficit of the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was recorded as a loss or gain on derivative liabilities. During the nine months ended September 30, 2023, the Company recorded $ 100,807 to gain on derivative liabilities in connection with these conversions. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $ 0.0008 to $ 0.004 , the closing stock price of the Company’s common stock on the date of valuation ranging from $ 0.001 to $ 0.006 , an expected dividend yield of 0 %, expected volatility ranging from 110 % to 193 %, risk-free interest rates ranging from 4.55 % to 5.37 %, and expected terms of 0.48 to 0.50 years. On September 30, 2023, the derivative liabilities on the remaining convertible notes were revalued at $ 292,699 93,836 0.0008 0.002 0 157 175 5.46 0.53 1 The Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to the effective interest method. During the nine months ended September 30, 2023, and 2022, the Company amortized $ 299,268 461,058 157,861	Note 7 – Convertible notes payable Convertible Notes Payable At various times during the year ended December 31, 2022, the Company entered into convertible promissory notes with principal amounts totaling $ 544,000 505,000 39,000 10 mature on dates ranging from January 1, 2023 to December 5, 2023 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. 267,136,056 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 7 – Convertible notes payable (continued) At various times during the year ended December 31, 2021, the Company entered into convertible promissory notes with principal amounts totaling $ 572,250 538,750 33,500 10 12 mature on dates ranging from January 25, 2022 to December 15, 2022 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. 95,273,690 Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the notes issued during the year ended December 31, 2022, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $ 674,971 171,245 0.0058 0.0143 0.008 0.0272 0 148 216 0.48 4.77 one year During the year ended December 31, 2022, convertible notes principal plus their accrued interest totaling $ 774,176 68,193,798 4,054,054 39,770 0.0038 0.016 0.006 0.026 0 63 191 0.51 4.74 0.44 0.50 On December 31, 2022, the derivative liabilities on the remaining convertible notes were revalued at $ 202,144 291,123 0.0038 0.006 0 96 120 4.71 0.49 0.93 For the notes issued during the year ended December 31, 2021, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $ 1,077,756 539,006 0.0039 0.0351 0.0217 0.0540 0 197 264 0.05 0.29 one year THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 7 – Convertible notes payable (Continued) During the year ended December 31, 2021, convertible notes principal plus their accrued interest totaling $ 529,735 21,690,671 489,279 0.0136 0.035 0.022 0.057 0 125 251 0.06 0.29 0.48 0.50 On December 31, 2021, the derivative liabilities on the remaining five convertible notes were revalued at $ 531,525 494,501 0.0123 0.0127 0.029 0 165 218 0.39 0.53 0.96 The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2022 and 2021, the Company amortized $ 593,463 541,612 175,063

Equity

Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Equity	Note 8 – Equity Our authorized capital stock consists of an aggregate of 5,505,000,000 5,500,000,000 0.001 5,000,000 3,450,665,355 2 Our non-controlling interest’s authorized capital stock consists of an aggregate of 505,000,000 500,000,000 0.0001 5,000,000 18,308,333 0 In 2022, we issued 44,500,000 445,000 In 2022, we issued 32,412,577 691,520 In 2022, we committed to issue 3,000,000 18,000 In 2022, we issued 4,812,259 67,399 In 2022, we issued 149,402,390 3,107,570 In 2022, we issued 11,000,000 242,320 In 2022, we issued 64,139,744 1,313,772 In 2022, we committed to issue 4,054,054 15,000 In 2023, we issued 445,180,614 677,378 In 2023, we issued 47,757,394 86,161 In 2023, we issued 4,081,632 20,000 In 2023, we issued 276,254,885 787,133 In 2023, we issued 60,000,000 96,000 On August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class On August 9, 2022, we issued 2 0.001 During the nine months ended September 30, 2023, the Company’s subsidiary, Res Nova Bio, Inc., issued shares of its common stock to third parties which represented 32 1,672 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023	Note 11 – Equity Our authorized capital stock consists of an aggregate of 3,505,000,000 3,500,000,000 0.001 5,000,000 2,617,390,830 2 In 2021, we issued 4,850,075 285,500 In 2021, we issued 21,000,000 858,900 In 2021, we issued 8,341,723 239,799 In 2021, we issued 1,500,000 58,900 In 2021, we issued 21,690,671 1,019,014 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 11 – Equity (continued) In 2022, we issued 44,500,000 445,000 In 2022, we issued 32,412,577 691,520 In 2022, we committed to issue 3,000,000 18,000 In 2022, we issued 4,812,259 67,399 In 2022, we issued 149,402,390 3,107,570 In 2022, we issued 11,000,000 242,320 In 2022, we issued 64,139,744 1,313,772 In 2022, we committed to issue 4,054,054 15,000

Subsequent events

Subsequent events	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent events	Note 9 – Subsequent events On October 2, 2023, we issued 2,500,000 0.0015 On October 5, 2023, we issued 35,702,240 34,274 On October 13, 2023, we filed an amendment of the articles of incorporation to increase the authorized shares from 4,505,000,000 5,505,000,000 5,500,000,000 5,000,000 On October 13, 2023, we issued 46,832,386 41,212 On October 16, 2023, we issued 60,000,000 90,000 On October 16, 2023, we issued 65,000,000 0.0015 On October 25, 2023, we issued 75,749,443 78,779 In accordance with ASC 855, the Company has analyzed its operations subsequent to November 17, 2022, through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.	Note 14 – Subsequent events On January 3, 2023, we issued 4,054,054 15,000 On January 3, 2023, we issued 17,000,000 0.006 On January 4, 2023, we issued 10,052,083 36,188 On January 9, 2023, we issued 4,081,632 20,000 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 14 – Subsequent events (continued) On January 9, 2023, we issued 4,000,000 0.049 On February 6, 2023, we issued 6,060,606 20,000 On February 7, 2023, we issued 11,386,719 36,438 On February 21, 2023, we issued 60,224,825 0.00216 On or about March 21, 2023, the Board of Directors of Therapeutic Solutions International, Inc. (“TSOI”), by unanimous approval, and with the unanimous approval of the Preferred A Stock holders representing at least 51% of all shareholders with the right to vote 0.0034 TSOI, which owns 15,660,000 31% 10,000,000 TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April 7, 2023 A letter will be mailed to every shareholder of record details of how to accept the Dividend Offer and a fully pre-paid return acceptance letter containing the necessary information for issuance. In addition, a Shareholder’s Rights Agreement will be enclosed, an executed copy to be returned with acceptance. Required forms and documents shall be filed with FINRA describing the identity of the parties and the Dividend Offer timely. In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2022 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 – Commitments and Contingencies Effective March 22, 2023, the Company entered into a sixth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 April 30, 2028 18,988 18,783 The lease will expire in 2028. The weighted average discount rate used for this lease is 5	Note 13 – Commitments and Contingencies Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 36 April 30, 2023 During the year ended December 31, 2022 and 2021, the Company incurred rent expense of $ 25,044 22,768 The lease will expire in 2023. The weighted average discount rate used for this lease is 5 Future minimum lease payments as of December 31, 2022 are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2023 $ 8,612 Effective November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.

Restricted cash

Restricted cash	12 Months Ended
	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Restricted cash	Note 3 – Restricted cash Included in current assets is a $ 10,000 0.6% This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related party transactions	Note 9 – Related party transactions As of December 31, 2019 and 2018, the Company had accrued officers’ salary of $ 439,534 and $ 663,100 , respectively. One of the officers settled with the company for a note payable that is unsecured on November 8, 2019 and doesn’t accrue interest and will be paid as 0.5 % of revenues. This decreased accrued officers’ salary. The note is still outstanding as of December 31, 2022 and 2021. Payments for the years ended December 31, 2022 and 2021 was $ 97 101 In 2021, we issued 7,544,848 239,800 On June 18, 2021, we issued 2,000,000 94,600 On November 30, 2021, we issued 7,000,000 224,000 In 2022, we issued 4,812,259 67,399 On April 5, 2022, we issued 7,000,000 175,700 On September 8, 2022, we issued 4,000,000 46,400 On November 2, 2022, we issued 3,000,000 29,700 On December 30, 2022, we committed to issue 14,000,000 $84,000 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income taxes	Note 10 – Income taxes The Company is subject to United States federal and state income taxes at an approximate rate of 30 Schedule of Income tax Expense December 31, 2022 December 31, 2021 Expected income tax at statutory rate $ (709,666 ) $ (621,735 ) State tax (101,347 ) 168 Permanent differences 405,376 404,872 Other - (71,992 ) Change in valuation allowance 406,437 289,487 Provision for income taxes $ 800 $ 800 The significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2022 December 31, 2021 Net operating loss carry-forward $ 2,364,249 $ 1,957,812 Valuation allowance (2,364,249 ) (1,957,812 ) Net deferred tax asset $ - $ - The Company has Federal net operating loss carryforwards of approximately $ 9.4 7.5 7.4 5.5 5 expires beginning in fiscal 2032 As of and for the years ended December 31, 2022 and 2021, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2022 and 2021. The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2019. The Company currently is not under examination by any tax authority.

Legal proceedings

Legal proceedings	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal proceedings	Note 12 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

Basis of presentation and sig_2

Basis of presentation and significant accounting policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.	Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc., its wholly owned subsidiaries, and its 68% owned subsidiary Res Nova Bio, Inc. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Our estimate of the provision for returns is based upon our most recent historical experience of actual customer returns. Additionally, we consider other factors when estimating our current period return provision, including levels of inventory in our distribution channel as well as significant market changes which may impact future expected returns, and make adjustments to our current period provision for returns when it appears product returns may differ from our original estimates. These returns have not been significant to the Company’s revenues in the accompanying financial statements. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock.	Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail. Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Returns. Shipping. Out of Stock.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0
Inventories	Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.	Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2023 and 2022, as disclosed in Note 7 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 292,699 202,144	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 202,144 531,525
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, 2023 and December 31, 2022, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the three months ended September 30, 2023 Schedule of Change in Derivative Liability Balance, December 31, 2022 $ 202,144 Issuance of new derivative liabilities 328,433 Conversions (331,714 ) Change in fair market value of derivative liabilities 93,836 Balance, September 30, 2023 $ 292,699	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2022 and 2021, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2022 and 2021: Schedule of Change in Derivative Liability Balance, December 31, 2020 $ 437,549 Issuance of new derivative liabilities 1,077,756 Conversions (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 531,525 Issuance of new derivative liabilities 674,971 Conversions (713,229 ) Change in fair market value of derivative liabilities (291,123 ) Balance, December 31, 2022 $ 202,144 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.
Non-Controlling Interests	Non-Controlling Interests Non-controlling interests disclosed within the consolidated statement of operations represent the minority ownership’s 32
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of September 30, 2023, and 2022, a total of 1,259,591,300 211,919,728 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2023	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2022 and 2021, a total of 267,136,056 95,273,690
Depreciation and Amortization	Depreciation and Amortization Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Amortization is computed using the straight-line method over the term of the agreement. Depreciation expense for the nine months ended September 30, 2023, and 2022 was $ 8,161 3,489	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $ 10,946 6,772
Intangible Assets	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the nine months ended September 30, 2023, and 2022 was $ 222,581 191,192	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $ 233,685 11,295
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.
Research and Development	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 410,146 1,177,123	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 1,441,128 794,750
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”	Income Taxes The Company accounts for income taxes under ASC 70 “Income Taxes” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued)
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.
Leases	Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 131,818	Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 8,612
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt —Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This update simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature and for convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this update amends the diluted earnings per share calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt the requirements of ASU 2020-06 using either a full or modified retrospective approach, and it is effective for public businesses, excluding entities eligible to be smaller reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The accounting guidance has been adopted with no significant financial statement impact. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.
Accounts Receivable		Accounts Receivable Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. The Company recorded an allowance for doubtful accounts of $ 6,807
Shipping and Handling		Shipping and Handling The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within general administrative expenses.
Advertising		Advertising Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $ 4,132 0

Basis of presentation and sig_3

Basis of presentation and significant accounting policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Change in Derivative Liability	The following is the change in derivative liability for the three months ended September 30, 2023 Schedule of Change in Derivative Liability Balance, December 31, 2022 $ 202,144 Issuance of new derivative liabilities 328,433 Conversions (331,714 ) Change in fair market value of derivative liabilities 93,836 Balance, September 30, 2023 $ 292,699
Schedule of Change in Derivative Liability		The following is the change in derivative liability for the years ended December 31, 2022 and 2021: Schedule of Change in Derivative Liability Balance, December 31, 2020 $ 437,549 Issuance of new derivative liabilities 1,077,756 Conversions (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 531,525 Issuance of new derivative liabilities 674,971 Conversions (713,229 ) Change in fair market value of derivative liabilities (291,123 ) Balance, December 31, 2022 $ 202,144

Prepaid expense and other cur_2

Prepaid expense and other current assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expense And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets September 30, 2023 December 31, 2022 Prepaid consulting $ 16,939 $ 148,550 Insurance 1,601 1,141 Prepaid costs and other 24,121 62,661 Total $ 42,661 $ 212,352	Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets December 31, 2022 December 31, 2021 Prepaid consulting $ 148,550 $ 930,893 Insurance 1,141 987 Prepaid costs 62,661 27,427 Total $ 212,352 $ 959,307

Fixed assets (Tables)

Fixed assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following: Schedule of Fixed Assets September 30, 2023 December 31, 2022 Land $ 347,381 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 6,135 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 413,517 301,359 Accumulated depreciation (36,441 ) (28,281 ) Property and equipment, net $ 377,076 $ 273,078	Fixed assets consist of the following: Schedule of Fixed Assets December 31, 2022 December 31, 2021 Land $ 235,223 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 301,359 301,159 Accumulated depreciation (28,281 ) (17,135 ) Property and equipment, net $ 273,078 $ 284,024

Other assets (Tables)

Other assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets consist of the following: Schedule of Other Assets September 30, 2023 December 31, 2022 Prepaid consulting $ - $ 7,537 Deposit 4,123 4,123 Licenses, net 2,780,379 3,002,960 Total $ 2,784,502 $ 3,014,620	Other assets consist of the following: Schedule of Other Assets December 31, 2022 December 31, 2021 Prepaid consulting $ 7,537 $ 108,673 Deposit 4,123 39,823 Licenses, net 3,002,960 129,075 Total $ 3,014,620 $ 277,571
Schedule of Net Licenses	Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses September 30, 2023 December 31, 2022 License $ 3,261,122 $ 3,261,122 Accumulated amortization (480,743 ) (258,162 ) Licenses, net $ 2,780,379 $ 3,002,960	Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses December 31, 2022 December 31, 2021 Licenses $ 3,261,122 $ 153,552 Accumulated amortization (258,162 ) (24,477 ) Licenses, net $ 3,002,960 $ 129,075

Restricted cash (Tables)

Restricted cash (Tables)	12 Months Ended
	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Schedule of Notes Payable Related Parties	Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2022 December 31, 2021 $ - $ 2,356 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ - $ 2,356 One notes payable – Chief Executive Officer, unsecured, including interest at 8 10 December 31, 2019 29,090 27,577 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,448 534,544 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 124,800 118,400 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 30,334 282,334 988,672 965,211 $ 988,672 $ 965,211

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Income tax Expense	Schedule of Income tax Expense December 31, 2022 December 31, 2021 Expected income tax at statutory rate $ (709,666 ) $ (621,735 ) State tax (101,347 ) 168 Permanent differences 405,376 404,872 Other - (71,992 ) Change in valuation allowance 406,437 289,487 Provision for income taxes $ 800 $ 800
Schedule of Deferred Tax Assets and Liabilities	The significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2022 December 31, 2021 Net operating loss carry-forward $ 2,364,249 $ 1,957,812 Valuation allowance (2,364,249 ) (1,957,812 ) Net deferred tax asset $ - $ -

Legal proceedings (Tables)

Legal proceedings (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of December 31, 2022 are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2023 $ 8,612

Organization and Business Des_2

Organization and Business Description (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended	194 Months Ended
	Aug. 04, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity incorporation date				Aug. 06, 2007		Aug. 06, 2007
Net income loss		$ 602,041	$ 946,462	$ 1,742,322	$ 2,738,142		$ 19,400,000
Unusual or infrequent item, description	the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.
Revenues						$ 17,300,000

Schedule of Change in Derivativ

Schedule of Change in Derivative Liability (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Beginning Balance	$ 202,144	$ 531,525	$ 437,549
Issuance of new derivative liabilities	328,433	674,971	1,077,756
Conversions	(331,714)	(713,229)	(489,279)
Change in fair market value of derivative liabilities	93,836	(291,123)	(494,501)
Ending Balance	$ 292,699	$ 202,144	$ 531,525

Basis of presentation and sig_4

Basis of presentation and significant accounting policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Payments description			Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.		Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
Cash, FDIC insured amount	$ 250,000		$ 250,000		$ 0	$ 0
Cash, uninsured amount	0		0		0
Derivative liabilities	292,699		$ 292,699		$ 202,144	$ 531,525
Antidilutive securities excluded from computation of earnings per share			1,259,591,300	211,919,728	267,136,056	95,273,690
Depreciation expense			$ 8,161	$ 3,489	$ 10,946	$ 6,772
Amortization expense			222,581	191,192	233,685	11,295
Research and development expense	148,879	$ 275,071	410,146	$ 1,177,123	1,441,128	794,750
Right-of-use asset	131,818		131,818		8,612	34,184
Lease liability	$ 131,818		$ 131,818		8,612
Allowance for doubtful accounts					6,807	6,807
Advertising expense					4,132	$ 0
Maximum [Member]
Property, Plant and Equipment [Line Items]
Cash, FDIC insured amount					$ 250,000
ResNova Bio Inc [Member]
Property, Plant and Equipment [Line Items]
Equity Method Investment, Ownership Percentage	32%		32%

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expense And Other Current Assets
Prepaid consulting	$ 16,939	$ 148,550	$ 930,893
Insurance	1,601	1,141	987
Prepaid costs	24,121	62,661	27,427
Total	$ 42,661	$ 212,352	$ 959,307

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total	$ 413,517	$ 301,359	$ 301,159
Accumulated depreciation	(36,441)	(28,281)	(17,135)
Property and equipment, net	377,076	273,078	284,024
Land [Member]
Property, Plant and Equipment [Line Items]
Total	347,381	235,223	235,223
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total	50,514	50,514	50,514
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	6,135	6,135	5,935
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	7,912	7,912	7,912
Shipping and Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,575	$ 1,575	$ 1,575

Fixed assets (Details Narrative

Fixed assets (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 8,161	$ 3,489	$ 10,946	$ 6,772

Schedule of Other Assets (Detai

Schedule of Other Assets (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid consulting		$ 7,537	$ 108,673
Deposit	4,123	4,123	39,823
Licenses, net	2,780,379	3,002,960	129,075
Total	$ 2,784,502	$ 3,014,620	$ 277,571

Schedule of Net Licenses (Detai

Schedule of Net Licenses (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Licenses	$ 3,261,122	$ 3,261,122	$ 153,552
Accumulated amortization	(480,743)	(258,162)	(24,477)
Licenses, net	$ 2,780,379	$ 3,002,960	$ 129,075

Other assets (Details Narrative

Other assets (Details Narrative) - USD ($)			3 Months Ended	9 Months Ended		12 Months Ended
	Mar. 25, 2022	Feb. 23, 2022	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization expenses				$ 222,581	$ 191,192	$ 233,685	$ 11,295
Amortization expenses						233,685	24,477
Stock Issued During Period, Value, New Issues			$ 189,026	677,378	445,000	$ 445,000	$ 285,499
Payments to Acquire Intangible Assets					$ 200,000
Exclusive Patent License Agreement [Member] | Convertible Promissory Note [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues		149,402,390
Share Price		$ 0.0208
Stock Issued During Period, Value, New Issues		$ 3,107,570
Patent expires agreement date		Dec. 31, 2032
Finite-Lived Intangible Assets, Remaining Amortization Period		10 years
AssetsTransfer And License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortized life of agreement	Mar. 24, 2027
AssetsTransfer And License Agreement [Member] | Initial Payment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to Acquire Intangible Assets	$ 200,000
AssetsTransfer And License Agreement [Member] | Second Payment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to Acquire Intangible Assets	$ 1,800,000

Notes Payable-Related Party (De

Notes Payable-Related Party (Details Narrative) - Officers and Directors [Member] - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Notes payable related party	$ 694,257		$ 988,672
Accrued interest	$ 3,956	$ 12,956

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Debt Instrument [Line Items]
Debt original issuance discount			$ 250,750	$ 415,000	$ 505,000	$ 538,750
Debt Conversion, Original Debt, Amount			249,565	415,000	503,726	538,750
Derivative liabilities	$ 292,699		292,699		202,144	531,525
Gain loss on derivative liabilities	(60,124)	$ (32,205)	(93,836)	233,303	291,123	494,501
Amortization of interest expenses			299,267	461,058	593,463	541,612
Convertible Notes [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount			338,577
Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Debt discount	$ 157,861		157,861
Amortization of interest expenses			299,268	$ 461,058
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt discount					175,063
Interest expenses					593,463	541,612
Derivative [Member]
Debt Instrument [Line Items]
Derivative issuance liability			628,437		674,971	1,077,756
Loss on derivative liability			$ 78,868		$ 171,245	$ 539,006
Derivative [Member] | Measurement Input, Conversion Price [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0008		0.0008		0.0058	0.0039
Derivative [Member] | Measurement Input, Conversion Price [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0034		0.0034		0.0143	0.0351
Derivative [Member] | Measurement Input, Share Price [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0011		0.0011		0.008	0.0217
Derivative [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.006		0.006		0.0272	0.0540
Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0		0		0	0
Derivative [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	1.24		1.24		148	197
Derivative [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	1.60		1.60		216	264
Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.67		4.67		0.48	0.05
Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	5.46		5.46		4.77	0.29
Derivative [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			1 year		1 year	1 year
Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 283,250		$ 283,250		$ 544,000	$ 572,250
Debt original issuance discount			250,750		505,000	538,750
Debt discount	$ 32,500		$ 32,500		$ 39,000	$ 33,500
Interest rate percentage	10%		10%		10%
Debt maturity date description			mature on dates ranging from April 11, 2024, to September 29, 2024		mature on dates ranging from January 1, 2023 to December 5, 2023	mature on dates ranging from January 25, 2022 to December 15, 2022
Debt conversion description			The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.		The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.	The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.
Common shares reserve | shares	1,259,591,300		1,259,591,300		267,136,056	95,273,690
Convertible Promissory Note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest rate percentage						10%
Convertible Promissory Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest rate percentage						12%
Convertible Notes [Member]
Debt Instrument [Line Items]
Loss on derivative liability					$ 39,770
Debt conversion of convertible shares | shares			218,504,885		68,193,798	21,690,671
Derivative, Gain on Derivative			$ 100,807
Debt conversion of convertible shares, value					$ 774,176	$ 529,735
Common stock, subscribed and issued | shares					4,054,054
Additional paid in capital on convertible debt features						$ 489,279
Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0008		0.0008		0.0038	0.0136
Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.004		0.004		0.016	0.035
Convertible Notes [Member] | Measurement Input, Share Price [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.001		0.001		0.006	0.022
Convertible Notes [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.006		0.006		0.026	0.057
Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0		0			0
Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	1.10		1.10		63	125
Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	1.93		1.93		191	251
Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.55		4.55		0.51	0.06
Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	5.37		5.37		4.74	0.29
Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			5 months 23 days		5 months 8 days	5 months 23 days
Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			6 months		6 months	6 months
Remaining Convertible Notes [Member]
Debt Instrument [Line Items]
Derivative liabilities	$ 292,699		$ 292,699		$ 202,144	$ 531,525
Gain loss on derivative liabilities			$ 93,836		$ 291,123	$ 494,501
Remaining Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares						0.0123
Remaining Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares						0.0127
Remaining Convertible Notes [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.002		0.002		0.006	0.029
Remaining Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0		0		0	0
Remaining Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	1.57		1.57		96	165
Remaining Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	1.75		1.75		120	218
Remaining Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	5.46		5.46		4.71	0.39
Remaining Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			6 months 10 days		5 months 26 days	6 months 10 days
Remaining Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			1 year		11 months 4 days	11 months 15 days
Remaining Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0008		0.0008		0.0038
Convertible Notes Payable [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input					0

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)												3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 25, 2023	Oct. 13, 2023	Oct. 05, 2023	Mar. 21, 2023	Feb. 21, 2023	Feb. 07, 2023	Feb. 06, 2023	Jan. 09, 2023	Jan. 04, 2023	Jan. 03, 2023	Aug. 04, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Aug. 09, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate authorized capital												5,505,000,000		5,505,000,000		3,505,000,000
Common stock, shares authorized		5,500,000,000										5,500,000,000		5,500,000,000		3,500,000,000	3,500,000,000
Common stock, par value												$ 0.001		$ 0.001		$ 0.001	$ 0.001
Preferred Stock, Shares Authorized		5,000,000										5,000,000		5,000,000		5,000,000	5,000,000
Common stock, shares outstanding												3,450,665,355		3,450,665,355		2,617,390,830	2,311,123,860
Preferred stock, shares outstanding												2		2		2	0
Common stock issued for cash												$ 189,026		$ 677,378	$ 445,000	$ 445,000	$ 285,499
Common stock issued for cash, shares												6,561	$ 100,878	86,161	508,078	691,520	858,900
Common stock issued for salaries														20,000	29,999	67,399	239,799
Common stock issued for license															3,107,570	3,107,570
Common stock issued for prepaid fees													93,500		242,320	242,320	1,472,450
Common stock issued for cash, shares												$ 129,414	$ 272,919	$ 787,133	$ 943,432	$ 1,313,772	$ 529,735
Preferred stock, voting rights											the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class
Preferred stock, shares issued												2		2		2	0	2
Preferred stock, par value												$ 0.001		$ 0.001		$ 0.001	$ 0.001	$ 0.001
Equity, Attributable to Noncontrolling Interest												$ 1,672		$ 1,672
Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares				15,660,000
Common stock issued for cash, shares								4,000,000		17,000,000
Land Development [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares																	1,500,000
Common stock issued for cash																	$ 58,900
ResNova Bio Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity Method Investment, Ownership Percentage												32%		32%
Convertible Notes Payable [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of convertible notes										4,054,054				276,254,885		64,139,744	21,690,671
Common stock issued for cash, shares										$ 15,000				$ 787,133		$ 1,313,772	$ 1,019,014
Convertible Notes Payable [Member] | Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of convertible notes		46,832,386				11,386,719	6,060,606		10,052,083	4,054,054
Common stock issued for cash, shares		$ 41,212				$ 36,438	$ 20,000		$ 36,188	$ 15,000
Land Development [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Conversion of convertible notes														60,000,000
Prepaid Fees [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares																11,000,000
Common stock issued for cash																$ 242,320
Common stock issued for prepaid fees, shares																11,000,000
Common stock issued for prepaid fees																$ 242,320
Salaries [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares																4,812,259	8,341,723
Common stock issued for cash																$ 67,399	$ 239,799
Common stock issued for salaries, shares														4,081,632		4,812,259
Common stock issued for salaries														$ 20,000		$ 67,399
Land Development [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for salaries														$ 96,000
Consulting Services [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares																32,412,577	21,000,000
Common stock issued for cash																$ 691,520	$ 858,900
Common stock issued for cash, shares										3,000,000				47,757,394		32,412,577
Common stock issued for cash, shares										$ 18,000				$ 86,161		$ 691,520
Consulting Services [Member] | Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash										18,000
Common stock issued for cash, shares										$ 3,000,000
License [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares																149,402,390
Common stock issued for cash																$ 3,107,570
Common stock issued for license, shares																149,402,390
Common stock issued for license																$ 3,107,570
Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares														445,180,614		44,500,000	4,850,075
Common stock issued for cash														$ 677,378		$ 445,000	$ 285,500
Private Placement [Member] | Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for cash, shares	75,749,443		35,702,240		60,224,825
Common stock issued for cash	$ 78,779		$ 34,274
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized												5,500,000,000		5,500,000,000
Common stock issued for cash, shares												175,089,179		445,180,614	44,500,000	44,500,000	4,850,075
Common stock issued for cash												$ 175,089		$ 445,180	$ 44,500	$ 44,500	$ 4,850
Common stock issued for cash, shares												1,757,394	9,302,577	47,757,394	25,302,577	32,412,577	21,000,000
Common stock issued for cash, shares												$ 1,757	$ 9,303	$ 47,757	$ 25,303	$ 32,413	$ 21,000
Common stock issued for salaries, shares														4,081,632	1,034,482	4,812,259	8,341,723
Common stock issued for salaries														$ 4,082	$ 1,034	$ 4,812	$ 8,342
Common stock issued for license, shares															149,402,390	149,402,390
Common stock issued for license															$ 149,402	$ 149,402
Common stock issued for prepaid fees, shares													5,000,000		11,000,000	11,000,000	20,000,000
Common stock issued for prepaid fees													$ 5,000		$ 11,000	$ 11,000	$ 20,000
Conversion of convertible notes												79,774,708	17,532,500	276,254,885	41,700,228	64,139,744	21,690,671
Common stock issued for cash, shares												$ 79,775	$ 17,533	$ 276,255	$ 41,700	$ 64,140	$ 21,691
Noncontrolling Interest [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate authorized capital												505,000,000		505,000,000
Common stock, shares authorized												500,000,000		500,000,000
Common stock, par value												$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized												5,000,000		5,000,000
Common stock, shares outstanding												18,308,333		18,308,333
Preferred stock, shares outstanding												0		0
Common stock issued for cash
Common stock issued for cash, shares
Common stock issued for salaries
Common stock issued for license
Common stock issued for prepaid fees
Common stock issued for cash, shares

Subsequent events (Details Narr

Subsequent events (Details Narrative) - USD ($)														3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 25, 2023	Oct. 16, 2023	Oct. 13, 2023	Oct. 05, 2023	Oct. 02, 2023	Mar. 21, 2023	Feb. 21, 2023	Feb. 07, 2023	Feb. 06, 2023	Jan. 09, 2023	Jan. 04, 2023	Jan. 03, 2023	Aug. 04, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Common stock issued for cash														$ 189,026		$ 677,378	$ 445,000	$ 445,000	$ 285,499
Capital Units, Authorized														5,505,000,000		5,505,000,000		3,505,000,000
Common stock, shares authorized			5,500,000,000											5,500,000,000		5,500,000,000		3,500,000,000	3,500,000,000
Preferred stock, shares authorized			5,000,000											5,000,000		5,000,000		5,000,000	5,000,000
Conversion of common stock														$ 129,414	$ 272,919	$ 787,133	$ 943,432	$ 1,313,772	$ 529,735
Right of voting													the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class
Minimum [Member]
Subsequent Event [Line Items]
Capital Units, Authorized			4,505,000,000
Maximum [Member]
Subsequent Event [Line Items]
Capital Units, Authorized			5,505,000,000
Private Placement [Member]
Subsequent Event [Line Items]
Common stock issued for cash, shares																445,180,614		44,500,000	4,850,075
Common stock issued for cash																$ 677,378		$ 445,000	$ 285,500
Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares												4,054,054				276,254,885		64,139,744	21,690,671
Conversion of common stock												$ 15,000				$ 787,133		$ 1,313,772	$ 1,019,014
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock issued for cash, shares						15,660,000
Shares issued for consulting services										4,000,000		17,000,000
Shares issued price per share										$ 0.049		$ 0.006
Subsequent Event [Member] | Campbell Neurosciences Inc [Member]
Subsequent Event [Line Items]
Dividend conversion rate						$ 0.0034
Common stock shares percentage						31%
Common stock divident						10,000,000
Dividend, description						TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April 7, 2023 (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for Ninety (90) days from the Dividend Offer Date
Dividend offer date						Apr. 07, 2023
Subsequent Event [Member] | Preferred Class A [Member] | Director [Member]
Subsequent Event [Line Items]
Right of voting						Preferred A Stock holders representing at least 51% of all shareholders with the right to vote
Subsequent Event [Member] | Accrued Salaries [Member]
Subsequent Event [Line Items]
Common stock issued for cash, shares										4,081,632
Common stock issued for cash										$ 20,000
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Common stock issued for cash, shares	75,749,443			35,702,240			60,224,825
Common stock issued for cash	$ 78,779			$ 34,274
Shares issued price per share							$ 0.00216
Subsequent Event [Member] | Consulting Services [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares		65,000,000			2,500,000
Common stock issued for consulting services per share		$ 0.0015			$ 0.0015
Subsequent Event [Member] | Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares			46,832,386					11,386,719	6,060,606		10,052,083	4,054,054
Conversion of common stock			$ 41,212					$ 36,438	$ 20,000		$ 36,188	$ 15,000
Subsequent Event [Member] | Accrued Salaries [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares		60,000,000
Conversion of common stock		$ 90,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)		9 Months Ended		12 Months Ended
	Mar. 22, 2023 ft²	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) ft²	Dec. 31, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Area of land | ft²	1,700			1,700
Lease expiration date	Apr. 30, 2028			Apr. 30, 2023
Payment for rent | $		$ 18,988	$ 18,783	$ 25,044	$ 22,768
Operating lease discount rate		5%		5%
Lease contract term				36 months

Schedule of Notes Payable Relat

Schedule of Notes Payable Related Parties (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Notes payable related party, non-current	$ 988,672	$ 965,211
Related Party [Member]
Short-Term Debt [Line Items]
Notes payable related party, current	988,672	965,211
Notes Payable One [Member]
Short-Term Debt [Line Items]
Notes payable related party, current		2,356
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable related party, current	29,090	27,577
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Notes payable related party, current	534,448	534,544
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Notes payable related party, current	124,800	118,400
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Notes payable related party, current	$ 30,334	$ 282,334

Schedule of Notes Payable Rel_2

Schedule of Notes Payable Related Parties (Details) (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Scientific Advisory Board [Member] | Notes Payable One [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt interest percentage	10%	10%
Debt maturity date	Dec. 31, 2019	Dec. 31, 2019
Chief Executive Officer [Member] | Notes Payable Two [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt maturity date	Dec. 31, 2019	Dec. 31, 2019
Chief Executive Officer [Member] | Notes Payable Two [Member] | Minimum [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt interest percentage	8%	8%
Chief Executive Officer [Member] | Notes Payable Two [Member] | Maximum [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt interest percentage	10%	10%
Chief Financial Officer [Member] | Notes Payable Four [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt interest percentage	8%	8%
Debt maturity date	Dec. 31, 2019	Dec. 31, 2019
Business Advisory Board [Member] | Notes Payable Five [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt maturity date	Apr. 20, 2019	Apr. 20, 2019
Business Advisory Board [Member] | Notes Payable Five [Member] | Minimum [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt interest percentage	8%	8%
Share price	$ 0.004	$ 0.004
Business Advisory Board [Member] | Notes Payable Five [Member] | Maximum [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt interest percentage	10%	10%
Share price	$ 0.005	$ 0.005

Restricted cash (Details Narrat

Restricted cash (Details Narrative)	12 Months Ended
	Dec. 31, 2022 USD ($)
Cash and Cash Equivalents [Abstract]
Restricted cash and non-cash equivalents	$ 10,000
Annual interest rate	0.60%
Restricted cash description	This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Related party transactions (Det

Related party transactions (Details Narrative) - USD ($)

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 30, 2022

Nov. 02, 2022

Sep. 08, 2022

Apr. 05, 2022

Nov. 30, 2021

Jun. 18, 2021

Sep. 30, 2023

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2019

Dec. 31, 2018

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Related Party Transaction, Rate

0.50%

Payments

$ 97

$ 101

Number of common stock issued, value

$ 189,026

$ 677,378

$ 445,000

$ 445,000

$ 285,499

Officer [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Accrued Salaries, Current

$ 439,534

$ 663,100

One Officers [Member] | Restricted Stock [Member] | Accrued Salaries [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Number of common stock issued

4,812,259

7,544,848

Number of common stock issued, value

$ 67,399

$ 239,800

One Officer And One Director [Member] | Restricted Stock [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Number of common stock issued

4,000,000

2,000,000

Number of common stock issued, value

$ 46,400

$ 94,600

Four Officer And One Director [Member] | Restricted Stock [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Number of common stock issued

14,000,000

7,000,000

7,000,000

Number of common stock issued, value

$ 84,000

$ 175,700

$ 224,000

Four Officer One Director [Member] | Restricted Stock [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Number of common stock issued

3,000,000

Number of common stock issued, value

$ 29,700

Schedule of Income tax Expense

Schedule of Income tax Expense (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Expected income tax at statutory rate					$ (709,666)	$ (621,735)
State tax					(101,347)	168
Permanent differences					405,376	404,872
Other						(71,992)
Change in valuation allowance					406,437	289,487
Provision for income taxes		$ 800	$ 800	$ 800	$ 800	$ 800

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carry-forward	$ 2,364,249	$ 1,957,812
Valuation allowance	(2,364,249)	(1,957,812)
Net deferred tax asset

Income taxes (Details Narrative

Income taxes (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal and state income taxes rate	30%
Federal net operating loss carryfowards	$ 9.4	$ 7.5
State net operating loss carryfowards	7.4	$ 5.5
Net operating loss carryforwards are available to offset taxable income	$ 5
Net operating loss carryforwards, expiration, description	expires beginning in fiscal 2032

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details)	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023	$ 8,612